We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

S32:ASXSouth32 Ltd. Analysis

Data as of 2026-03-13 - not real-time

A$4.41

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

South32 is trading at AUD 4.41, just below its 20‑day SMA of 4.47 but comfortably above the 50‑day SMA of 4.34, indicating a short‑term bullish bias. The 200‑day SMA sits at 3.36, showing a long‑term uptrend. Technical momentum is mixed: the RSI sits at 49, near the neutral zone, while the MACD histogram is negative (‑0.04) signaling bearish pressure. Volume has been increasing, supporting the price rally toward the resistance level of 4.75. The stock’s beta of 0.82 and 30‑day volatility of 41% suggest moderate market sensitivity with elevated price swings. Valuation metrics are stretched, with a trailing P/E of 36.8 versus a forward P/E of 11.1 and a DCF‑derived fair value of 3.05, implying the market is pricing a premium.
Fundamentally, revenue fell 2.6% year‑over‑year and free cash flow is negative, while debt‑to‑equity stands at a high 18.2, raising concerns about balance‑sheet resilience. Nonetheless, the company maintains a 2.14% dividend yield with a payout ratio of 68%, though sustainability is questionable given cash flow constraints. Analyst consensus remains positive (13 analysts, “buy”) and the upside/downside metric shows an 8% upside to current price. Geographic diversification across Australia, Brazil, South Africa and other regions spreads risk but adds regulatory and currency exposure. The sector’s commodity‑linked nature adds medium‑level sector risk. Overall, the stock appears overvalued relative to intrinsic estimates, but the dividend and improving forward earnings provide some support.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price just above short‑term SMA20 indicating near‑term support
  • Increasing volume supporting upward momentum
  • Bearish MACD histogram suggesting caution

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward P/E of 11.1 implying earnings growth potential
  • Analyst consensus of ‘buy’ with 13 coverage
  • Dividend yield of 2.14% offering income while price remains near resistance

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • High debt‑to‑equity and negative free cash flow
  • Overvaluation relative to DCF fair value
  • Diversified commodity exposure creating sector and commodity cycle risk

Key Metrics & Analysis

Financial Health

Revenue Growth-2.60%
Profit Margin5.37%
P/E Ratio36.8
ROE4.24%
ROA3.37%
Debt/Equity18.25
P/B Ratio1.5
Op. Cash FlowA$1.4B
Free Cash FlowA$-141124992

Technical Analysis

TrendBullish
RSI49.4
SupportA$4.16
ResistanceA$4.75
MA 20A$4.47
MA 50A$4.34
MA 200A$3.36
MACDBearish
VolumeIncreasing
Fear & Greed Index72.57

Valuation

Fair ValueA$3.05
Target PriceA$4.76
Upside/Downside8.03%
GradeOvervalued
TypeBlend
Dividend Yield2.14%

Risk Assessment

Beta0.82
Volatility41.45%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.